Ranbaxy Laboratories Ltd.
NSE: RANBAXY | BSE: 500359
₹859.80
₹45.80
(5.63%)
As on 01-Apr-2015IST
Market cap
₹36,603 Cr
Revenue (TTM)
₹5,759 Cr
P/E Ratio
--
P/B Ratio
14
Div. Yield
0 %
Stock Range
Today’s Range
52 Week Range
Liquidity
Fundamentals
-
Net Profit (TTM)
₹-1,073 Cr
-
ROE
-29.3 %
-
ROCE
-2 %
-
Industry P/E
41.91
-
EV/EBITDA
36.8
-
Debt to Equity
5.7
-
Book Value
₹--
-
EPS
₹-3.1
-
Face value
5
-
Shares outstanding
425,663,497
10 Years Aggregate
CFO
₹2,039.65 Cr
EBITDA
₹8,416.45 Cr
Net Profit
₹152.79 Cr
Performance
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Ranbaxy Lab
| 36.9 | 20.7 | 36.9 | 135.6 | 22.4 | 12.6 | 5.5 |
|
BSE Sensex*
| -9.1 | -1.5 | 2.9 | -3.6 | 5.9 | 6.0 | 10.5 |
|
BSE Healthcare#
| 18.1 | 1.0 | 9.6 | 17.6 | 22.5 | 14.1 | 12.2 |
|
Company
|
2014
|
|---|---|
|
Ranbaxy Lab
| 35.7 |
|
BSE Sensex
| 29.9 |
|
BSE Healthcare
| 47.4 |
Essential Checks
View DetailsIs there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
Financials
View DetailsKey Ratios
View Details
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Peers
View DetailsCompany |
Price (₹) | Market Cap (₹ Cr) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Ranbaxy Lab
|
859.8 | 36,602.8 | 5,759.4 | -135.8 | -3.0 | -10.5 | -- | 14.0 |
| 3,174.3 | 25,979.8 | 1,461.8 | 387.4 | 34.5 | 25.2 | 67.3 | 15.1 | |
| 843.9 | 16,595.8 | 7,784.0 | 688.5 | 10.6 | 14 | 23.9 | 2.8 | |
| 460.0 | 17,589.9 | 2,141.5 | 58.5 | 5.8 | 3.3 | 165.6 | 4.6 | |
| 837.2 | 20,755.5 | 5,632.3 | 662.4 | 17.2 | 14.3 | 31.3 | 4.2 | |
| 1,527.9 | 17,502.0 | 1,543.3 | -48.6 | 3.6 | -0.6 | -- | 3.0 | |
| 213.2 | 28,384.3 | 9,205.3 | -371.8 | 1.7 | -3.8 | -- | 3.5 | |
| 1,822.2 | 30,127.6 | 1,935.8 | 288.2 | 20.6 | 29.8 | 104.5 | 22.4 | |
| 402.1 | 16,213.4 | 3,600.2 | 221.0 | 9.7 | 5.6 | 73.4 | 3.4 | |
| 1,850.6 | 30,074.9 | 3,564.0 | 414.0 | 15.3 | 8.4 | 73.5 | 6.0 |
Shareholding Pattern
View DetailsNews & Analysis
All News
3 min read•By Mohammed Ekramul Haque
2 min read•By Mohammed Ekramul Haque and Vikas Vardhan
Companies operating with wide margins
2 min read•By Mohammed Ekramul Haque
2 min read•By Mohammed Ekramul Haque
1 min read•By Vikas Vardhan
2 min read•By Research Desk
About Ranbaxy Lab
Manufacture of pharmaceuticals, medicinal chemical and botanical products
-
Incorporated
1961
-
Chairman
Tsutomu Une
-
Managing Director
Arun Sawhney
-
Group
MNC
-
Headquarters
Mohali, Punjab
-
Website
Value Research Ratings
Our rating system has guided millions of investors in the past 20 years.
FAQs for Ranbaxy Lab
What is the current share price of Ranbaxy Laboratories Ltd Today?
The share price of Ranbaxy Laboratories Ltd is ₹859.80 (NSE) and ₹859.90 (BSE) as of 01-Apr-2015 IST. Ranbaxy Laboratories Ltd has given a return of 22.35% in the last 3 years.
What is the current PB & PE ratio of Ranbaxy Laboratories Ltd?
Since, TTM earnings of Ranbaxy Laboratories Ltd is negative, P/E ratio is not available.
The P/B ratio of Ranbaxy Laboratories Ltd is 13.98 times as on 01-Apr-2015, a 224 premium to its peers’ median range of 4.32 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
2012 |
23.04 |
5.24 |
2011 |
0.00 |
6.00 |
2010 |
16.84 |
4.51 |
2009 |
73.37 |
5.24 |
2008 |
0.00 |
2.59 |
What is the 52 Week High and Low of Ranbaxy Laboratories Ltd?
The 52-week high and low of Ranbaxy Laboratories Ltd are Rs -- and Rs -- as of 01-Sep-2026.
What is the market cap of Ranbaxy Laboratories Ltd?
Ranbaxy Laboratories Ltd has a market capitalisation of ₹ 36,603 Cr as on 01-Apr-2015. As per SEBI classification, it is a company.
Should I invest in Ranbaxy Laboratories Ltd?
Before investing in Ranbaxy Laboratories Ltd, assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.